Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab

NCT04363853 is registered in ClinicalTrials.gov with Instituto Nacional de Cancerologia de Mexico as lead sponsor.

NCT NCT04363853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04363853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab
Lead sponsor
Instituto Nacional de Cancerologia de Mexico
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 1, 2020
Completion date
December 31, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov2